Heron's Groundhog Day; Vifor forms JV with Fresenius Kabi in China
→ Another delay has blighted Heron Therapeutics‘ quest to get its long-acting non-opioid painkiller for post-surgical analgesia on to the US market. The company, whose …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
